XOMA Royalty Corp. XOMA
40.17 USD 0.00 (+0.00%)
At closeJul 13, 2026, 4:00 PM EDT
42.15 +1.98 +4.93%
After hours · Jul 13, 4:00 PM ET
39.87 Day range 43.53
18.03 52-week range 35.00
- YTD
- +51.07%
- 1 year
- +47.04%
- Market cap
- 313.66M
- Revenue (ttm)
- 21.61M
- Profit margin
- -138.67%
- EPS (ttm)
- -3.07
- Shares out
- 11.78M
- P/E ratio
- 44.39
- Forward P/E
- -56.64
- Dividend
- 2.16 (7.99%)
- Ex-dividend date
- Jan 2, 2025
- YTD return
- +51.07%
- 1-year return
- +47.04%
- Avg volume
- 29.44K
- Open
- 43.53
- Previous close
- 40.17
- Day's range
- 39.87 – 43.53
- 52-week range
- 18.03 – 35.00
- Beta
- 0.90
- Analysts
- Buy
- Price target
- 89.00 (+121.6%)
2Y +11.58 (+40.50%)
Key statistics
- Enterprise value
- 295.82M
- PEG ratio
- 0.00
- Price / sales
- 14.52
- Price / book
- 3.69
- Dividend yield
- 7.99%
- Payout ratio
- 0.00%
- Revenue growth
- 767.10%
- Free cash flow
- -19.24M
- Total cash
- 142.84M
- Total debt
- 118.94M
- Return on equity
- -31.41%
- Short % of float
- 1.39%
- 50-day average
- 29.85
- 200-day average
- 26.96
Analyst view
Consensus: buy
Buy
Price target (mean) 89.00 +121.6% upside
Now 40.17
- Target (low)
- 55.00
- Target (mean)
- 89.00
- Target (high)
- 123.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
XOMA Revenue — quarterly 12.32M
XOMA Net income — quarterly 2.12M
XOMA EPS — quarterly 0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.44 | -0.39 | +0.05 | +11.36% |
| Aug 13, 2024 | Jun 1, 2024 | -0.26 | -0.28 | -0.02 | -7.69% |
| May 9, 2024 | Mar 1, 2024 | -0.71 | -0.86 | -0.15 | -21.13% |
| Mar 8, 2024 | Dec 1, 2023 | -0.36 | -0.49 | -0.13 | -36.11% |
| Nov 7, 2023 | Sep 1, 2023 | -0.48 | -0.60 | -0.12 | -25.00% |
| Aug 8, 2023 | Jun 1, 2023 | -0.52 | -0.59 | -0.07 | -13.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About XOMA Royalty Corp.
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- xoma.com
News
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital 
Dimensional Fund Advisors LP Boosts Stock Holdings in XOMA Royalty Corporation $XOMA 
XOMA Royalty Announces Closing of Its Acquisition by Ligand 
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets 
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date 
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? 
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—TMHC, CZR, XOMA, and AVNS 
Saying Goodbye To The XOMA Royalty PFDs 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO) 
This Appian Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday
Your note
Sign in to keep a note on XOMA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS THOMAS M | Chief Financial Officer | Sale | Nov 12, 2024 | 20,107 |
| BVF PARTNERS L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 5, 2023 | 0 |
| HERNDAY NATASHA A | Director | Stock Award(Grant) | May 14, 2024 | 3,035 |
| HUGHES OWEN | Chief Executive Officer | Sale | Nov 12, 2024 | 34,979 |
| PERRY MATTHEW D | Director | Stock Award(Grant) | May 14, 2024 | 17,869 |
| SITKO BRADLEY J. | Chief Investment Officer | Purchase | Oct 2, 2023 | 7,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 30.84% | 3,633,743 | 96.73M | Sep 29, 2024 |
| FMR, LLC | 9.36% | 1,102,401 | 29.35M | Sep 29, 2024 |
| Blackrock Inc. | 4.55% | 535,658 | 14.26M | Sep 29, 2024 |
| Vanguard Group Inc | 3.58% | 422,394 | 11.24M | Sep 29, 2024 |
| Opaleye Management Inc. | 2.12% | 250,000 | 6.66M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 1.66% | 195,096 | 5.19M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Capital Appreciation Fund | 2.51% | 296,000 | 7.88M | Oct 30, 2024 |
| Fidelity Advisor Equity Growth Fund | 2.47% | 290,628 | 7.74M | Oct 30, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 2.17% | 255,512 | 6.80M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.15% | 252,910 | 6.73M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.64% | 193,330 | 5.15M | Oct 30, 2024 |
| Fidelity Growth Discovery Fund | 1.25% | 147,667 | 3.93M | Oct 30, 2024 |